Some COVID-19 patients still have coronavirus after symptoms disappear

New York, NY, USA (March 27, 2020) — In a new study, researchers found that half of the patients they treated for mild COVID-19 infection still had coronavirus for up to eight days after symptoms disappeared. The research letter was published online in the American Thoracic Society’s American Journal of Respiratory and Critical Care Medicine.

In „Time Kinetics of Viral Clearance and Resolution of Symptoms in Novel Coronavirus Infection,“ Lixin Xie, MD, Lokesh Sharma, PhD, and co-authors report on a study of 16 patients with COVID-19, who were treated and released from the Treatment Center of PLA General Hospital in Beijing between January 28 and Feb. 9, 2020. Patients studied had a median age of 35.5 years.

Researchers collected samples from throat swabs taken from all patients on alternate days and analyzed. Patients were discharged after their recovery and confirmation of negative viral status by at least two consecutive polymerase chain reaction (PCR) tests.

„The most significant finding from our study is that half of the patients kept shedding the virus even after resolution of their symptoms,“ said co-lead author Dr. Sharma, instructor of medicine, Section of Pulmonary, Critical Care & Sleep Medicine, Department of Medicine, Yale School of Medicine. „More severe infections may have even longer shedding times.“

The primary symptoms in these patients included fever, cough, pain in the pharynx (pharyngalgia) and difficult or labored breathing (dyspnea). Patients were treated with a range of medications.

The time from infection to onset of symptoms (incubation period) was five days among all but one patient. The average duration of symptoms was eight days, while the length of time patients remained contagious after the end of their symptoms ranged from one to eight days. Two patients had diabetes and one had tuberculosis, neither of which affected the timing of the course of COVID-19 infection.

„If you had mild respiratory symptoms from COVID-19 and were staying at home so as not to infect people, extend your quarantine for another two weeks after recovery to ensure that you don’t infect other people,“ recommended corresponding author Lixin Xie, MD, professor, College of Pulmonary and Critical Care Medicine, Chinese PLA General Hospital, Beijing.

The authors had a special message for the medical community: „COVID-19 patients can be infectious even after their symptomatic recovery, so treat the asymptomatic/recently recovered patients as carefully as symptomatic patients.“

The researchers emphasized that all of these patients had milder infections and recovered from the disease, and that the study looked at a small number of patients. They noted that it is unclear whether similar results would hold true for more vulnerable patients such as the elderly, those with suppressed immune systems and patients on immunosuppressive therapies.

„Further studies are needed to investigate if the real-time PCR-detected virus is capable of transmission in the later stages of COVID-19 infection,“ Dr. Xie added.

About the American Journal of Respiratory and Critical Care Medicine

The AJRCCM is a peer-reviewed journal published by the American Thoracic Society. The Journal takes pride in publishing the most innovative science and the highest quality reviews, practice guidelines and statements in pulmonary, critical care and sleep medicine. With an impact factor of 16.494, it is one of the highest ranked journals in pulmonology. Editor: Jadwiga Wedzicha, MD, professor of respiratory medicine at the National Heart and Lung Institute (Royal Brompton Campus), Imperial College London, UK.

About the American Thoracic Society

Founded in 1905, the American Thoracic Society is the world’s leading medical association dedicated to advancing pulmonary, critical care and sleep medicine. The Society’s 15,000 members prevent and fight respiratory disease around the globe through research, education, patient care and advocacy. The ATS publishes three journals, the American Journal of Respiratory and Critical Care Medicine, the American Journal of Respiratory Cell and Molecular Biology and the Annals of the American Thoracic Society.


American Thoracic Society, 27.03.2020 (tB).

MEDICAL NEWS

Novel biomarker discovery could lead to early diagnosis for deadly…
Why do more women have Alzheimer’s than men? It’s not…
New research highlights potential cardiovascular risk of novel anti-osteoporotic drug
Asymptomatic COVID-19 patients also contaminate the environment
At height of COVID-19, nurses and doctors reported high levels…

SCHMERZ PAINCARE

DBfK: Besondere Rolle für Pflegeexpert/innen Schmerz – nicht nur in…
Vagus-Stimulation: Neuartige Strom-Impulse lindern Schmerz
Aktuelle Aspekte der Anwendung von Cannabinoiden in Schmerz- und Palliativmedizin:…
Deutsche Gesellschaft für Neurologie (DGN): Ingwerextrakt hilft nicht zur Prophylaxe…
„LONTS“ – Langzeitanwendung von Opioiden bei nicht tumorbedingten Schmerzen: Dt.…

DIABETES

Continuous glucose monitoring reduces hypoglycemia in older adults with type…
COVID-19 may trigger new diabetes, experts warn
„Körperstolz“: Michael Krauser managt seinen Diabetes digital
Der richtige Sensor – von Anfang an
Diabetes mellitus: Ein Risikofaktor für frühe Darmkrebserkrankungen

ERNÄHRUNG

Corona-Erkrankung: Fehl- und Mangelernährung sind unterschätze Risikofaktoren
Gesundheitliche Auswirkungen des Salzkonsums bleiben unklar: Weder der Nutzen noch…
Robert Koch-Institut: Fast Food, Bio-Lebensmittel, Energydrinks – Journal of Health…
Neue Daten zur Ernährungssituation in deutschen Krankenhäusern und Pflegeheimen: Mangelernährung…
Baxter: Parenterale Ernährung von Patienten mit hohem Aminosäurenbedarf

ONKOLOGIE

Eisenmangel/-anämie bei Tumorpatienten: Frühzeitige Diagnose und Therapie sind entscheidend
Gentest zur Vorbeugung von Chemotherapie-Nebenwirkungen. Alte Substanzen vor neuen Herausforderungen
Fortbildung für Pflegende zum „OncoCoach“
Hochauflösende 3D-Ansicht des Tumorinneren bei Brustkrebs mit optoakustischer Mesoskopie
Angst vor COVID-19 verzögert Diagnose und Therapie bei Krebspatienten

MULTIPLE SKLEROSE

Multiple Sklerose: Novartis’ Siponimod verzögert Krankheitsprogression und Hirnatrophie bei aktiver…
Neurofilamente als Diagnose- und Prognosemarker für Multiple Sklerose
Case series: Teriflunomide therapy in COVID-19 patients with MS
Bedeutung der Langzeittherapie bei Multipler Sklerose – mehr Sicherheit und…
Einige MS-Medikamente könnten vor SARS-CoV-2/COVID-19 schützen

PARKINSON

Neue Studie zur tiefen Hirnstimulation bei Parkinson-Erkrankung als Meilenstein der…
Parkinson-Patienten in der Coronakrise: Versorgungssituation und ein neuer Ratgeber
Neuer Test: Frühzeitige Differenzialdiagose der Parkinson-Erkrankung
Gegen das Zittern: Parkinson- und essentiellen Tremor mit Ultraschall behandeln…
Projekt VAFES: Expertenteam entwickelt Diagnosesystem für Parkinson-Patienten